.Attributes Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of clients along with HER2+ advanced bosom cancer cells and energetic or even dependable brain metastases presented consistent intracranial task and systemic efficacy of T-DXd.